A carregar...
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
BACKGROUND: Since December 2019, COVID-19 has spread to almost every corner of the world. In theory, tocilizumab and favipiravir are considered to be reliable drugs for the treatment of COVID-19 with elevated IL-6. We aimed to assess the efficacy and safety of tocilizumab combined with favipiravir i...
Na minha lista:
| Publicado no: | Biomed Pharmacother |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Published by Elsevier Masson SAS.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524677/ https://ncbi.nlm.nih.gov/pubmed/33378989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopha.2020.110825 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|